Month: March 2022

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology’s Broad Applicability Across Molecule Type and Therapeutic Area Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based...

Pilot Nodule Collector Allseas-designed pilot nodule collector undergoes wet-test trialsEpsilon Carbon Epsilon Carbon’s existing infrastructure demonstrates capabilities in green technologies such as battery anodes.Nodule Collector Trials Monitoring wet-test commissioning of Allseas-designed pilot nodule collectorNEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today provided financial results for the fourth quarter and full year ending December 31, 2021, and announced a corporate update. Q4 2021 and FY 2021 Financial HighlightsTotal cash of approximately $84.9 million, at December 31, 2021. Existing cash balance expected to be sufficient to fund TMC’s operations into the...

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) — Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for full-year ended December 31, 2021 and provided an overview of the Company’s recent corporate developments. “We continue to believe in the potential of YTX-7739, which may represent a major advancement in the treatment paradigm for Parkinson’s patients,” said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity. “As previously announced, to preserve capital and optimize shareholder value, we took several rapid steps recently including engaging H.C. Wainwright to evaluate strategic alternatives for the Company; implementing...

SAN JOSE, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the fiscal year ended December 31, 2021. As of December 31, 2021, the Fund’s net assets were approximately $94.8 million, or $13.75 per share, compared with net assets of approximately $102.1 million, or $14.82 per share as of December 31, 2020. As of December 31, 2021, the Fund’s portfolio included public and private securities valued at approximately $91.1 million, or $13.22 per share, which includes approximately $0.09 per share in cash and cash equivalents. Portfolio Summary (as of 12/31/21)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $90.50 million $13.13Cash/Cash...

FY21 revenue of $16.9 million met high end of revenue outlookCompany provides outlook for continued growth in FY22 Newtown, PA, March 24, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for the quarter and year ended December 31, 2021. “We have achieved many milestones in the last year,” said Max Wygod, Forian Executive Chairman. “We have grown revenue tremendously, won key accounts, built out the Forian team and completed the acquisition of Helix Technologies, not to mention successfully listing on Nasdaq.” Forian Chief Executive Officer Dan Barton said, “We had our highest revenue quarter as a result of strong focus on sales execution and continued investment in...

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the full year ended December 31, 2021. “I am very gratified by the clinical progress Imago has made in 2021, underlined by the positive and promising interim Phase 2 data in both essential thrombocythemia (ET) and myelofibrosis (MF) presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Additionally, Imago made great strides as a company with a successful initial public offering on Nasdaq and expansion of our Board,” said Dr. Hugh Young Rienhoff, Jr., M.D, Chief Executive Officer of Imago BioSciences. “Looking...

WINNIPEG, Manitoba, March 24, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2021 financial results. Fourth Quarter Financial HighlightsTotal Revenue for the three months ended December 31, 2021 was $411,693, an increase of 60% compared to $257,339 for the three months ended December 30, 2020. This increase is primarily attributable to increased pet retail sales. Gross profit for the fourth quarter of 2021 was $187,315, an increase of 82% compared to $102,717 for the quarter ended December 31, 2020. Total Operating expenses for the three months ended December 31, 2021 were $1,490,686, an increase of 28% compared to $1,168,493 for the quarter ended December 31, 2020. This increase is due primarily to increased research expenditures...

– Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study – – Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid tumors – – Previously reported $35 million private placement expected to extend cash runway into the second quarter of 2023 and fund ongoing GoCAR-T clinical development programs – HOUSTON, March 24, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2021 and provided an operational update. “Bellicum made great progress in the past year in the clinical development of our GoCAR-T® cell...

– Fourth Quarter and Full Year Revenue Increased 25% and 27%, Respectively – – Ongoing Commercial Progress in Core Markets and Refined Strategic Focus Provide Strong Foundation for Growth in 2022 – – Reiterating Previously Provided 2022 Guidance – BOCA RATON, Fla., March 24, 2022 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (Nasdaq: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2021. All financial information is provided in US dollars unless otherwise indicated. Fourth Quarter 2021 Summary vs. Same Year-Ago QuarterRevenue increased 25% to $4.2 million compared to $3.3 million. Cannabinoid revenue...

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter and full year ended December 31, 2021. Management is hosting an earnings call today at 4:30 p.m. ET. The fourth quarter and full year 2021 was marked by meaningful corporate, financial and clinical progress. 2021 and early 2022 Highlights:Agreed to acquire Cancer Prevention Pharmaceuticals, Inc. (CPP) setting the stage for a combined entity with an expanded pipeline addressing an estimated $5 billion aggregated market opportunity upon closing. Initiated our ASPIRE trial – a global, randomized, double-blind, placebo controlled Phase II/III clinical trial...